NASDAQ:NPCE NeuroPace (NPCE) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free NPCE Stock Alerts $8.50 +0.53 (+6.65%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$7.65▼$8.6550-Day Range$7.97▼$15.3352-Week Range$3.80▼$18.15Volume336,451 shsAverage Volume117,894 shsMarket Capitalization$244.53 millionP/E RatioN/ADividend YieldN/APrice Target$15.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get NeuroPace alerts: Email Address NeuroPace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside84.3% Upside$15.67 Price TargetShort InterestHealthy0.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 21 Articles This WeekInsider TradingSelling Shares$7.58 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.14) to ($1.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.20 out of 5 starsMedical Sector346th out of 925 stocksSurgical & Medical Instruments Industry45th out of 100 stocks 3.4 Analyst's Opinion Consensus RatingNeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeuroPace has only been the subject of 3 research reports in the past 90 days.Read more about NeuroPace's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.65% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroPace has recently decreased by 7.52%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuroPace does not currently pay a dividend.Dividend GrowthNeuroPace does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NPCE. Previous Next 2.0 News and Social Media Coverage News SentimentNeuroPace has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for NeuroPace this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for NPCE on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuroPace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,583,250.00 in company stock.Percentage Held by Insiders27.50% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NeuroPace's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for NeuroPace are expected to decrease in the coming year, from ($1.14) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroPace is -7.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroPace is -7.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroPace has a P/B Ratio of 17.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NeuroPace's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in seven months. So if you currently own NVIDIA (NVDA)... Or were thinking of buying it in the weeks ahead... I urge you to review my recent interview with 50-year Wall Street legend Marc Chaikin.You can watch it here. About NeuroPace Stock (NASDAQ:NPCE)NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Read More NPCE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NPCE Stock News HeadlinesMay 4, 2024 | insidertrades.comInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 4,674 Shares of StockApril 27, 2024 | insidertrades.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Orbimed Advisors Llc Sells 1,781 SharesMay 12, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 24, 2024 | insidertrades.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $345,756.45 in StockApril 19, 2024 | insidertrades.comInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 2,623 Shares of StockApril 16, 2024 | insidertrades.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $6,692,916.51 in StockMay 12, 2024 | americanbankingnews.comNeuroPace, Inc. (NASDAQ:NPCE) to Post FY2028 Earnings of $0.27 Per Share, Leerink Partnrs ForecastsMay 10, 2024 | finance.yahoo.comNeuroPace Inc (NPCE) Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Ongoing ChallengesMay 12, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. May 10, 2024 | markets.businessinsider.comNeuroPace’s Strong Q1 Performance and Promising Growth Prospects Affirm Buy RatingMay 9, 2024 | finanznachrichten.deNeuroPace, Inc: NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | finance.yahoo.comNeuroPace Inc (NPCE) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Improved ...May 9, 2024 | americanbankingnews.comNeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 8, 2024 | msn.comNeuroPace GAAP EPS of -$0.32May 8, 2024 | globenewswire.comNeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | markets.businessinsider.comNeuroPace is about to announce its earnings — here's what Wall Street expectsMay 5, 2024 | americanbankingnews.comOrbimed Advisors Llc Sells 4,674 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockMay 5, 2024 | americanbankingnews.comOrbimed Advisors Llc Sells 15,690 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockApril 20, 2024 | investing.comOrbiMed Advisors sells shares in NeuroPace worth over $238,000April 17, 2024 | globenewswire.comNeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024April 10, 2024 | fool.comNeuroPace (NASDAQ: NPCE)April 4, 2024 | msn.com'Biggest mistake' bond investors may make ahead of Fed rate cutsMarch 27, 2024 | globenewswire.comNeuroPace to Present at the Needham 23rd Annual Healthcare ConferenceMarch 13, 2024 | markets.businessinsider.comThe Latest Analyst Ratings For NeuroPaceMarch 7, 2024 | markets.businessinsider.comNeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth DriversMarch 7, 2024 | finance.yahoo.comNeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comNeuroPace Full Year 2023 Earnings: EPS Beats ExpectationsSee More Headlines Receive NPCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/12/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NPCE CUSIPN/A CIK1528287 Webwww.neuropace.com Phone650-237-2700FaxN/AEmployees171Year FoundedN/APrice Target and Rating Average Stock Price Target$15.67 High Stock Price Target$22.00 Low Stock Price Target$9.00 Potential Upside/Downside+84.3%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,960,000.00 Net Margins-45.61% Pretax Margin-45.61% Return on Equity-173.62% Return on Assets-30.89% Debt Debt-to-Equity Ratio4.05 Current Ratio6.43 Quick Ratio5.02 Sales & Book Value Annual Sales$65.42 million Price / Sales3.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book17.00Miscellaneous Outstanding Shares28,768,000Free Float20,822,000Market Cap$244.53 million OptionableOptionable Beta2.06 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Martha J. Morrell (Age 67)Chief Medical Officer Comp: $555.87kMr. Joel D. Becker (Age 56)CEO, President & Director Ms. Rebecca L. Kuhn (Age 63)CFO, VP of Finance & Administration and Assistant Secretary Comp: $440.92kMs. Kelley NicholasVice President of SalesMs. Irene Thomas (Age 55)Vice President of Human Resources Key CompetitorsPulmonxNASDAQ:LUNGBioventusNYSE:BVSAnika TherapeuticsNASDAQ:ANIKBeauty HealthNASDAQ:SKINPulse BiosciencesNASDAQ:PLSEView All CompetitorsInsiders & InstitutionsHillsdale Investment Management Inc.Bought 11,750 shares on 5/11/2024Ownership: 0.041%Vanguard Group Inc.Bought 75,512 shares on 5/10/2024Ownership: 1.701%Acadian Asset Management LLCBought 47,215 shares on 5/10/2024Ownership: 0.164%Orbimed Advisors LlcSold 4,674 sharesTotal: $65,576.22 ($14.03/share)Orbimed Advisors LlcSold 15,690 sharesTotal: $219,973.80 ($14.02/share)View All Insider TransactionsView All Institutional Transactions NPCE Stock Analysis - Frequently Asked Questions Should I buy or sell NeuroPace stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NPCE shares. View NPCE analyst ratings or view top-rated stocks. What is NeuroPace's stock price target for 2024? 7 equities research analysts have issued 12 month price targets for NeuroPace's stock. Their NPCE share price targets range from $9.00 to $22.00. On average, they anticipate the company's stock price to reach $15.67 in the next year. This suggests a possible upside of 84.3% from the stock's current price. View analysts price targets for NPCE or view top-rated stocks among Wall Street analysts. How have NPCE shares performed in 2024? NeuroPace's stock was trading at $10.31 at the start of the year. Since then, NPCE stock has decreased by 17.6% and is now trading at $8.50. View the best growth stocks for 2024 here. When is NeuroPace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our NPCE earnings forecast. How were NeuroPace's earnings last quarter? NeuroPace, Inc. (NASDAQ:NPCE) announced its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.10. The firm had revenue of $18.01 million for the quarter, compared to analysts' expectations of $17.74 million. NeuroPace had a negative net margin of 45.61% and a negative trailing twelve-month return on equity of 173.62%. What ETF holds NeuroPace's stock? iShares Neuroscience and Healthcare ETF holds 788 shares of NPCE stock, representing 0.29% of its portfolio. What guidance has NeuroPace issued on next quarter's earnings? NeuroPace issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $73.0 million-$77.0 million, compared to the consensus revenue estimate of $75.2 million. When did NeuroPace IPO? NeuroPace (NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers. Who are NeuroPace's major shareholders? NeuroPace's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.70%), Acadian Asset Management LLC (0.16%) and Hillsdale Investment Management Inc. (0.04%). Insiders that own company stock include Accelmed Partners Ii LP, Irina Ridley, Ltd Kck, Martha Morrell and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of NeuroPace? Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NPCE) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward PressMissed NVDA? Buy this AI stock NOWChaikin Analytics[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICYou need to know these two things about AI stocks ASAP…InvestorPlaceCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.